Category - Developments

Developments

EMA grants orphan designation to Can-Fite’s CF102

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) oncology drug candidate, CF102, has been granted orphan drug designation by the European Medicines Agency (EMA) for the indication of hepatocellular carcinoma (HCC), the...

October 12, 2015

Developments

Dipexium hits 50% enrollment in second Phase 3 trial

Dipexium Pharmaceuticals’ (NASDAQ: DPRX) OneStep-2 pivotal Phase 3 clinical trial has reached the 50% enrollment milestone. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials, with 180 patients in...

October 1, 2015

Developments

Cellectar gets NCI grant for PDC platform

Cellectar Biosciences (NASDAQ:CLRB) has received initial notice of award for a Phase I-II Fast-Track Small Business Innovation Research (SBIR) grant. The SBIR grant provides up to $2.3-million over 2 1/2 years from the...

October 1, 2015

Developments

Novadaq, Arthrex to sell combined endoscopic system

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has entered into a co-marketing agreement with Arthrex, a global medical device company and leader in orthopedic medical device innovation. The agreement allows the two...

October 1, 2015

Developments

Vital outlines plans for new Phase 3 ELAD trial

Vital Therapies (NASDAQ:VTL) has outlined plans for a possible new Phase 3 clinical trial designed to confirm ELAD’s safety and efficacy in alcohol-induced liver decompensation (AILD), including severe acute alcoholic...

September 28, 2015

Developments

Novadaq unveils SPY-Q Case Manager software

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has unveiled its SPY-Q Case Manager (SPY-QCM) software at the Symposium on Advanced Wound Care Fall 2015 meeting in Las Vegas. SPY-QCM is an image acquisition and analysis...

September 28, 2015

Developments

BioLight’s Eye-D to be featured at Boston conference

BioLight Life Sciences Investments’ (OTCQX:BLGTY; TASE:BOLT) Eye-D platform insert will be presented at the 5thAnnual Partnership Opportunities in Drug Delivery conference in Boston on Oct. 5. The Eye-D is BioLight’s...

September 24, 2015

Developments

Oramed gets patent for oral administration of proteins

The United States Patent and Trademark Office has approved Oramed Pharmaceuticals’ (NASDAQ: ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.” In a statement, CEO...

September 24, 2015

Developments

Dipexium presents Locilex data at ICAAC/ICC

Dipexium Pharmaceuticals and research collaborators, JMI Laboratories, have presented new Locilex microbiology data at the American Society for Microbiology’s Interscience Conference of Antimicrobial Agents and...

September 21, 2015

Developments

Braeburn Pharma commends HHS plan on opioid addition

Closely-held Braeburn Pharmaceuticals has commended U.S. Department of Health and Human Services (HHS) Secretary Sylvia Burwell on her announcement that HHS will expand access to medication-assisted treatment as part of...

September 18, 2015

Category - Developments

EMA grants orphan designation to Can-Fite’s CF102

Dipexium hits 50% enrollment in second Phase 3 trial

Cellectar gets NCI grant for PDC platform

Novadaq, Arthrex to sell combined endoscopic system

Vital outlines plans for new Phase 3 ELAD trial

Novadaq unveils SPY-Q Case Manager software

BioLight’s Eye-D to be featured at Boston conference

Oramed gets patent for oral administration of proteins

Dipexium presents Locilex data at ICAAC/ICC

Braeburn Pharma commends HHS plan on opioid addition

General

More